Three Republican State AGs Just Sued Trump’s DOJ to Stop Cannabis Rescheduling. Here’s Why That’s a Bigger Deal Than It Sounds.

The Republican attorneys general suing to block Trump’s marijuana rescheduling aren’t just being contrarian. They’re making a procedural argument that, if it sticks, could freeze federal cannabis reform in place regardless of who’s in the White House — now or in 2028.

Three state AGs filed suit against the Department of Justice in late May, challenging the administration’s move to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. Their core claim: the rescheduling action is unlawful. Not because they necessarily oppose it as a policy outcome, but because of how it’s being done.

That distinction is crucial. And it’s why this lawsuit deserves more attention than it’s getting.

What the AGs Are Actually Arguing

Federal drug scheduling isn’t supposed to happen by executive decree. The Controlled Substances Act sets out a formal process: the DEA conducts a scientific review, accepts public comment, and holds administrative hearings before any substance can be moved up or down the schedule. The Trump administration, according to the lawsuit, has been trying to short-circuit or compress that process in ways the plaintiffs argue violate the plain language of the law.

The DEA has been holding hearings — the upcoming June proceeding has drawn participants from both pro-rescheduling cannabis operators and prohibitionist groups seeking to halt it. But the AGs’ argument is that the White House has been applying pressure on the DEA timeline and framing in ways that corrupt the independence of the administrative review. Whether that pressure rises to the level of an “unlawful” action is what a federal court will now have to decide.

Legal observers who follow administrative law note that this kind of separation-of-functions challenge is genuinely difficult to win. Courts have historically given executive agencies wide deference on rulemaking timelines. But the challenge doesn’t have to win to matter — it can create injunctive delay, push rescheduling past a political window, or force the administration to restart portions of the rulemaking process.

Why Republican AGs Are Doing This

It would be a mistake to read this as simply an ideological anti-cannabis move, even though all three AGs are from Republican-led states that have not legalized adult-use cannabis. The politics inside the GOP on cannabis have fragmented significantly over the past 18 months.

A portion of the Republican coalition — particularly law enforcement lobbies, some evangelical networks, and traditional social conservatives — remains staunchly opposed to any federal normalization of marijuana. These groups have lobbied AGs in red states aggressively since Trump’s rescheduling order became public. Three of those AGs listened.

But there’s also a federalism argument at play. Some state-level Republicans who have opposed cannabis legalization at home are uncomfortable with the federal government rewriting drug policy in ways that could complicate their own enforcement regimes — particularly in states that still aggressively prosecute marijuana possession and have statutory schemes built around Schedule I classification.

If cannabis moves to Schedule III at the federal level, state laws that depend on the federal Schedule I designation as a predicate — for licensing, employment disqualification, or enhanced sentencing — begin to look legally unstable. That’s a real concern for states that have spent years building enforcement infrastructure around the current federal framework.

The Broader Pattern: Courts as the New Rescheduling Battlefield

This lawsuit isn’t arriving in a vacuum. Courts have become the primary arena for cannabis policy disputes in 2026, and the dockets are crowded.

Earlier in May, a federal judge rejected a lawsuit from prohibitionist groups that had sought to halt a Centers for Medicare & Medicaid Services pilot program dispensing hemp-derived products to Medicare beneficiaries. The judge found that none of the plaintiffs could demonstrate sufficient “concrete harm” to establish standing — a threshold that challengers of executive cannabis policy keep stumbling over.

The AG lawsuit faces the opposite problem: states generally do have standing to challenge federal agency action, which means this case gets past the starting gate. Whether it goes further depends on the merits of the administrative law challenge, and those merits are genuinely contested.

NORML and allied advocacy groups have already flagged the lawsuit as a potentially significant obstruction. Democratic lawmakers, who sent a letter to the Trump administration in late May urging it to use pardon power to commute sentences for all federally incarcerated nonviolent marijuana offenders, are watching the litigation carefully. A successful injunction against rescheduling would strand thousands of people in federal prison for conduct that, under Schedule III, would be treated very differently.

What the Numbers Actually Say About Where States Stand

The lawsuit underscores a durable political reality: federal cannabis reform doesn’t map neatly onto party lines at the state level, and the gap between where voters are and where state governments are remains enormous.

Gallup polling has consistently shown support for cannabis legalization above 70 percent nationally. In states whose AGs just filed this lawsuit, that number doesn’t crater — even conservative-leaning states typically show 55-65 percent support for at least medical access. The AGs are not acting with a clear popular mandate here.

Forty-plus states now have some form of legal medical or adult-use cannabis program. That means even states whose AGs oppose federal rescheduling are running regulated cannabis markets — often with agencies that depend on the murky federal-state gap that Schedule III would partially close.

Schedule III wouldn’t legalize cannabis federally. It would reduce some criminal penalties for medical-use possession, lift the most egregious 280E tax burdens for compliant operators, and require a prescription model for true federal legality. But it would also trigger new FDA oversight requirements, inject federal compliance costs into state-licensed markets, and create exactly the kind of regulatory uncertainty that cannabis operators have been trying to exit for years.

The three AGs may actually be doing the industry a perverse favor by slowing a process that, if rushed, could create as many problems as it solves.

What Comes Next

The case will likely land in federal district court within weeks. Expect an early motion for a preliminary injunction — the AGs will try to pause the rescheduling process while the merits are litigated. If that motion succeeds, the DEA’s June hearing becomes legally complicated territory.

Watch also for intervention. The cannabis industry has legal standing to participate as a party in federal rulemaking challenges. Operators, trade groups like NCIA, and advocacy organizations will need to decide quickly whether to file amicus briefs or seek formal intervenor status — the same move prohibitionist groups have used in earlier litigation.

The rescheduling fight was always going to get ugly. Three Republican AGs just confirmed it.